Allergy Therapeutics PLC
LSE:AGY
Allergy Therapeutics PLC
LSE:AGY
Price:
2.875 GBX
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one
AGY
stock under the Base Case scenario is
2.678
GBX.
Compared to the current market price of 2.875 GBX,
Allergy Therapeutics PLC
is
Overvalued by 7%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AGY
Relative Value
Base Case
2.678
GBX
Overvaluation 7%
Valuation Multiples
Multiples Across Competitors
AGY Competitors Multiples
Allergy Therapeutics PLC Competitors
Allergy Therapeutics PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Allergy Therapeutics PLC
LSE:AGY
|
137m GBP | 2.6 | -2.7 | -3.8 | -3.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
698.5B USD | 19.4 | 113.8 | 55.8 | 63.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.3 | 33.1 | 36.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
359.3B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
322.8B USD | 5.3 | 140 | 33.3 | 52.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
173.2B CHF | 3 | 15.1 | 8.6 | 10.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157B USD | 2.9 | -508.1 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
